Spectrum gets rights to ImmunGene\'s IO platform and related assets

Spectrum gets rights to ImmunGene's IO platform and related assets

15:40 EDT 10 May 2019 | Elsevier Business Intelligence

Spectrum Pharmaceuticals Inc. licensed exclusive global rights to ImmunGene Inc.’s Focused Interferon Therapeutics (FIT) an...

Original Article: Spectrum gets rights to ImmunGene's IO platform and related assets

More From BioPortfolio on "Spectrum gets rights to ImmunGene's IO platform and related assets"